

**PRVNÍ DODATEK KE SMLouvĚ O KLINICKÉM
HODNOCENÍ**

První dodatek („**Dodatek**“) ke Smlouvě o klinickém hodnocení, uzavřené s účinností od 15. srpna 2022 („**Smlouva**“), mezi **Fakultní nemocnicí Hradec Králové**, Sokolská 581, 500 05 Hradec Králové - Nový Hradec Králové, Česká republika, IC: 00179906, DIC: CZ00179906, zastoupenou MUDr. Alešem Hermanem, Ph.D., ředitelem („**Poskytovatel zdravotních služeb**“) a **IV. Interní hematologická klinika**, zaměstnanec Poskytovatele zdravotních služeb („**Hlavní zkoušející**“) a **AbbVie, s. r. o.**, Metronom Business Center, Bucharova 2817/13, Stodůlky, 158 00 Praha 5, Česká republika, IČ: 24148725, DIČ: CZ24148725, zastoupené jednatelem MUDr. Branislavem Trutzem („**AbbVie**“) na poskytování služeb uvedených v Protokolu č. **M22-132** s názvem „**Otevřená studie fáze 1b/2 hodnotící bezpečnost a toleranci epcoritamabu v kombinaci s antineoplastickými látkami/immunoterapií u osob s non-Hodgkinovým lymfomem**“.

S ohledem na řádné plnění tohoto Dodatku a v souladu s podmínkami Smlouvy, se smluvní strany dohodly pozměnit Smlouvu následovně:

1. Rozpočet stanovený v Příloze A Smlouvy se zrušují v celém svém rozsahu a nahrazují se příloženými Přílohou A.

Pojmy, jež zde nejsou definovány jinak, mají stejný význam, který je jim připisován ve Smlouvě. Kromě podmínek, které se výslovně změnily tímto Dodatkem, zůstávají všechny ostatní podmínky této Smlouvy v plné platnosti a účinnosti během trvání této Smlouvy.

Předpokládaná hodnota Smlouvy ve znění tohoto Dodatku představuje **38.508.962, - Kč**.

**FIRST AMENDMENT TO THE CLINICAL STUDY
AGREEMENT**

First Amendment (the “**Amendment**“) to that certain Clinical Study Agreement effective 15 August 2022 (the “**Agreement**“), between **Fakultní nemocnice Hradec Králové**, Sokolská 581, postcode 500 05 Nový Hradec Králové, Czech Republic, Company ID: 00179906, Tax ID: CZ00179906, represented by MUDr. Aleš Herman, Ph.D., Director (the “**Provider of Medical Services**“) and **IV. Hematology Clinic**, employee of Provider of Medical Services (the “**Principal Investigator**“) and **AbbVie s.r.o.**, Metronom Business Center, Bucharova 2817/13, Stodůlky, 158 00 Praha 5, Czech Republic, ID: 24148725, VAT ID: CZ24148725, represented by Branislav Trutz, MD, General Manager and Executive (“**AbbVie**“) for services relating to Protocol No **M22-132** entitled “**Phase 1b/2, Open Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents/Immunotherapies in Subjects with Non-Hodgkin Lymphoma**“.

Subject to the full execution of this Amendment and in accordance with the terms of the Agreement, the parties hereby agree to amend the Agreement, as follows:

1. The Budget set forth in Exhibit A of the Agreement shall be deleted in its entirety and replaced with the attached Exhibit A.

Terms not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement. Except as specifically amended by this Amendment, all other terms and conditions of the Agreement shall continue in full force and effect during the term of the Agreement.

Anticipated value of the Agreement amended by the Amendment is **CZK 38,508,962**

CONFIDENTIAL

NA DŮKAZ ČEHOŽ každá smluvní strana prostřednictvím svých řádně zmocněných zástupců uvedla tuto smlouvu v platnost svým podpisem.

IN WITNESS WHEREOF, each of the parties has caused this Amendment to be executed by its authorized representative in its name and on its behalf.

AbbVie s.r.o.

Fakultní nemocnice Hradec Králové

By/Podepsal: _____

By/Podepsal: _____

Name/Jméno: **Mgr. Jan Balzer**

Name/Jméno: **MUDr. Aleš Herman, Ph.D.**

Title/Funkce: Country Clinical Operations Manager
Upon the power of attorney / Na základě plné moci

Title/Funkce: Director / ředitel

Date/Datum: 18. 7. 2023

Date/Datum: 21. 7. 2023


By/Podepsal: _____

Name/Jméno: _____

Title/Funkce: Principal Investigator / Hlavní zkoušející

Date/Datum: 21. 7. 2023

CONFIDENTIAL



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_ CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK 03Jul23
Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 3 of 40

2023-06-20T13:56:15

Attachment 1 to Exhibit A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 4 of 40

2023-06-20T13:56:15



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 5 of 40

2023-06-20T13:56:15



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 6 of 40

2023-06-20T13:56:15



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 7 of 40

2023-06-20T13:56:15



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0


Page 8 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Attachment 4 to Exhibit A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 10 of 40

2023-06-20T13:56:15



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 11 of 40

2023-06-20T13:56:15



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 12 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 13 of 40

2023-06-20T13:56:15

Attachment 6 to Exhibit A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 14 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 15 of 40

2023-06-20T13:56:15

Attachment 7 to Exhibit A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 16 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0


Page 17 of 40

2023-06-20T13:56:15

Attachment 8 to Exhibit A




CONFIDENTIAL




CONFIDENTIAL

Attachment 9 to Exhibit A



CONFIDENTIAL

Attachment 10 to Exhibit A



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_ CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK 03Jul23

Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 21 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_ CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK 03Jul23


Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 22 of 40

2023-06-20T13:56:15

Doplněk 1 k Příloze A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 23 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 24 of 40

2023-06-20T13:56:15

Doplněk 2 k Příloze A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 25 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0


Page 26 of 40

2023-06-20T13:56:15

Doplněk 3 k Příloze A



CONFIDENTIAL



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 28 of 40

2023-06-20T13:56:15

Doplněk 4 k Příloze A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 29 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 30 of 40

2023-06-20T13:56:15

Doplněk 5 k Příloze A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 31 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 32 of 40

2023-06-20T13:56:15

Doplněk 6 k Příloze A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 33 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 34 of 40

2023-06-20T13:56:15

Doplněk 7 k Příloze A



CONFIDENTIAL


Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011

Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 35 of 40

2023-06-20T13:56:15



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0


Page 36 of 40

2023-06-20T13:56:15

Doplněk 8 k Příloze A



CONFIDENTIAL



CONFIDENTIAL

Legal Template: Czech Republic-Amendment to the Clinical Study Agreement-24May2011


Document Name: 00220599.1_CZ M22-132 AMD no. 1 CZ CSA Template 1 Agmt Per Site (AbbVie Mngd Std) FN HK [REDACTED] 03Jul23 Final to MV

Version: 7/3/2023 3:37 PM, 3806, 0

Page 38 of 40


2023-06-20T13:56:15

Doplněk 9 k Příloze A



CONFIDENTIAL

Doplněk 10 k Příloze A



CONFIDENTIAL